Cytiva's Global Biopharma Index Highlights Talent and Regulatory Challenges in the Industry

What's Happening?

Cytiva has released its third Global Biopharma Index, surveying 1,250 biopharma executives across 22 countries. The survey evaluates the biopharma ecosystem based on six pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government policy, and regulation, with sustainability added as a new pillar in 2025. The global average score has decreased to 5.96 from 6.08 in 2023. The United States has dropped from second to fifth place due to regulatory uncertainty and policy disruption. The survey indicates that supply chain resilience is improving, but challenges remain in supporting advanced modalities like cell and gene therapies. Talent shortages persist, particularly in areas related to advanced drug modalities and sustainability.

Why It's Important?

The findings of the Global Biopharma Index are significant as they highlight the ongoing challenges faced by the biopharma industry, particularly in the United States. The drop in the U.S. ranking underscores the impact of regulatory uncertainty on the industry's ability to innovate and bring new therapies to market. Talent shortages in critical areas could hinder the development and manufacturing of advanced therapies, affecting the industry's growth and competitiveness. The emphasis on sustainability reflects a growing priority across industries, yet many companies are struggling to meet their targets due to financial pressures. These challenges could influence policy decisions and investment strategies in the biopharma sector.

What's Next?

The report suggests that continued evolution and collaboration between government agencies and industry partners are essential to meet global demands. Companies may need to focus on strengthening their supply chains and addressing talent shortages to improve their resilience. The industry might also see increased domestic manufacturing of biologics in response to geopolitical volatility. As sustainability becomes a strategic priority, companies may need to balance short-term financial pressures with long-term environmental goals. The findings could prompt policymakers to create more consistent and supportive regulatory environments to facilitate industry growth.

Beyond the Headlines

The shift from globalization to regional perspectives, as noted in the report, could have long-term implications for the biopharma industry. This trend may lead to more localized production and innovation, potentially affecting global collaboration and market dynamics. The emphasis on sustainability and the challenges in achieving these goals highlight the need for a cultural shift within companies to prioritize environmental responsibility alongside financial performance. The industry's ability to adapt to these changes will be crucial in maintaining its role in global healthcare innovation.